Dermatitis refer to the inhibitors that treat skin inflammation, which is characterised by itchy rashes on swollen and reddish skin, in the outer layer of the body. It is a general term that describes a common skin irritation. The main classes of drugs in dermatitis are corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators, and interleukin inhibitors. Corticosteroids are a group of steroid hormones generated by vertebrates' adrenal cortex and are also synthetic equivalents of these hormones. The different routes of administration include topical, oral, and injectable and are used in cancer, blood disorders, chronic diseases, and infectious diseases. It is distributed through various channels such as hospitals, retail pharmacies, drug stores, and online or mail pharmacies. The dermatitis market research report is one of a series of new reports from The Business Research Company that provides dermatitis market statistics, including dermatitis industry global market size, regional shares, competitors with a dermatitis market share, detailed dermatitis market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatitis industry. This dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global dermatitis market size will grow from $6.46 billion in 2022 to $6.89 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global dermatitis market size is expected to grow to $8.57 billion in 2027 at a CAGR of 5.6%. Growth in the atopic dermatitis market is primarily driven by the increasing global prevalence of the disease. The prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in adults. The rising cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for the medicines to cure this disease. For example, according to the allergy asthma network 2020, approximately 31.6 million people in the United States have some form of atopic dermatitis. The prevalence of atopic dermatitis globally in children have 15-20 percent and in adults have 1 to 3 percent. The strict government regulations are one of the restraints for the dermatitis drug market. Atopic Dermatitis (eczema) usually occurs at a very early stage (0-5 years). To find the efficacy and efficiency of the drug, it has to be tried on every type of patient. The effects of certain drugs in adults are quite different than in children, as a reasonable result of the clinical trial cannot be used for the production of drugs that will be served to the children. This hinders the research and requires more effort in clearing regulations set by FDA. For example, as the patient population is largely children, the FDA in its CFR Code Title 21, Part 50 Protection of Human Subjects, and subpart D has laid down guidelines for the additional safeguard for children in clinical investigation. The regulation complies with the Children’s Health Act of 2000 which requires all children subjected to clinical trials to be given additional protection. The dermatitis market has witnessed a trend of increasing mergers and acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today's world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolios and improve their market presence. Companies are also strategically making M&As to reduce competition and increase the scalability of their businesses. For instance, in January 2020, Eli Lilly and Company, a US-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of human drugs, acquired Dermira, Inc. for an amount of $1.1 billion. Through this acquisition, Lebrikizumab, an innovative, experimental monoclonal antibody, has been added to the immunology pipeline and marketed dermatology medicines in the product portfolio of Eli Lilly for the treatment of moderate-to-severe atopic dermatitis in patients 12 years of age and older. Dermira, Inc. is a US-based biopharmaceutical company pioneering in the discovery and development of novel therapies for dermatology patients. The dermatitis drugs market is governed by several regulatory bodies that require the drug manufacturers to get approvals from the concerned authorities before launching their medicines into the market. Two such major regulatory bodies are PMDA (Japan) and CDSCO (India) which carry out quality checks before declaring the drugs suitable for consumption. PMDA reviews the products to ensure the safety, quality, and efficacy of pharmaceuticals and then approves the products that are suitable in every parameter. Similarly, CDSCO is the central drug authority that is responsible for the approval of new drugs in India. These tedious approval processes make the drugs more effective and safe, thereby having a positive impact on the dermatitis drugs market. Major players in the dermatitis market are LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer HealthCare, Encore Dermatology Inc., Meda Pharmaceuticals, Allergan PLC. (Republic of Ireland) and Bristol-Myers Squibb. North America was the largest region in the dermatitis market in 2022. Middle East is expected to be the fastest-growing region in the global dermatitis market during the forecast period. The regions covered in the global dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The dermatitis market consists of sales of Stasis dermatitis, atopic dermatitis, and irritant contact dermatitis. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global dermatitis market is segmented - 1) By Drug Class: Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors 2) By Distribution Channel: Hospital, Retail Pharmacies, Drug Stores, Online Or Mail Pharmacies 3) By Route Of Application: Topical, Oral, Injectable 4) By Application: Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases

The cold and cough preparations refer to the medications that are used to treat cold and cough. The drugs for the treatment of cold and cough act on the receptors to which the virus causing the infection gets attached, by antagonizing the action of the receptors and killing the viral infection, thereby reducing congestion by lysing the mucus and dilating the bronchioles constricted by the mucus deposition. The main types of drugs in cold and cough preparations are antihistamines, expectorants, bronchodilators, decongestants, antibiotics, and others. Antihistamines are drugs or other compounds that block the physiological effects of histamine and are used to treat allergies in particular. The different types include bronchodilators, anticholinergic, and pulmonary antihypertensives. The several dosage types include oral syrups, tablets or pills, nasal drops, lozenges, and others and are distributed through various channels such as hospital pharmacies, retail pharmacies, and drug stores. The cold and cough preparations market research report is one of a series of new reports from The Business Research Company that provides cold and cough preparations market statistics, including cold and cough preparations industry global market size, regional shares, competitors with a cold and cough preparations market share, detailed cold and cough preparations market segments, market trends and opportunities, and any further data you may need to thrive in the cold and cough preparations industry. This cold and cough preparations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cough and cold preparations market size will grow from $66.75 billion in 2022 to $70.37 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cough and cold preparations market size is expected to grow to $84.02 billion in 2027 at a CAGR of 4.5%. The rising incidence of allergies is expected to fuel the growth of the cough and cold preparations market in the forecast period. There are many respiratory allergies such as pollen, dust, mold, and pet allergies; these allergies are caused due to contaminated outdoor and indoor air. Cough and cold preparations are consumed for treating allergies, which cause cough and cause issues in the respiratory tract. For instance, according to the European Academy of Allergy and Clinical Immunology, a non-profit organization for European clinicians, researchers, and allied health professionals, by 2025, 1 in every 3 people in the European Union is expected to be affected by allergies. Thus, the increase in the incidence of respiratory allergies will bolster the demand for cough and cold preparations, positively affecting the growth of the market. Threat from substitute products such as generic and counterfeit drugs is significantly restraining the global cold and cough preparations market. Pharmaceutical companies invest a large sum of money in the drug development process. Once a drug candidate is developed and approved by the regulatory authorities, companies patent their inventions to protect their intellectual property. During the patency period, the company holding the patent holds exclusivity for manufacturing and distribution. Post expiration of patency, generic versions of the drugs is manufactured by other companies. The prices of the generics are very low in comparison to the original brand of the drug. According to an article by Alpha InvesCo., a new FDA-approved blockbuster drug that netted $100 million a year in profit during its patent protection duration could become one that earns only $1 million a year in profit overnight after losing its patent. Additionally, there is a major international problem with counterfeit drugs. The best of these counterfeits duplicates a real drug’s formula and sells it at a lower price, which hurts pharmaceutical companies' profits. Moreover, counterfeits made with low-grade materials can destroy the reputations of legitimate products, thus affecting the growth of the market. Advancements in technologies are driving the global pharmaceutical sector including cold and cough preparations. According to a global life sciences report by Deloitte, the adoption of AI, robotic automation, the Internet of Medical Things (IoMT), blockchain, DIY diagnostics, virtual care, mobility in drug delivery and clinical trials, genomics, next-generation therapies, cloud computing, Real-World Evidence (RWE), and data-driven precision medicine are the major technologies driving the life sciences sector. AI technology is being used in diagnoses, treatment planning, patient monitoring, and drug discovery. The IoMT is allowing new business models to emerge and enhancing customer experiences. Pharmaceutical companies are also increasingly using biomarkers in the drug development process to reduce the time taken to bring the product into the market. Biomarkers are biological indicators that are objectively measured and evaluated for biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. The cold and cough preparations market is regulated by authorities such as the Food and Drug Administration in the US. For instance, the Food and Drug Administration (FDA) restricted the use of codeine in children. Codeine is approved to treat pain and cough but this medicine carries serious risks, including slowed or difficult breathing, and can be potentially fatal. This risk is greater in children younger than 12 years but the use of codeine should also be limited in some older children. Single-ingredient codeine is FDA-approved only for use in adults. FDA is also recommending against the use of codeine in breastfeeding mothers due to possible harm to their infants. Major players in the cold and cough preparation market are AstraZeneca, Bayer, Blackmores Limited, Dabur, GlaxoSmithKline, Himalaya Global Holdings, Hyland's, Johnson & Johnson, Novartis and Perrigo Company. North America was the largest region in the cold and cough preparation market in 2022. Middle East is expected to be the fastest-growing region in the global cough and cold preparations market during the forecast period. The regions covered in the global cold and cough preparation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cold and cough preparations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cold and cough preparations market consists of sales of dextromethorphan, guaifenesin, and phenylephrine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cough and cold preparations market is segmented - 1) By Type: Bronchodialators, Anticholinergic, Pulmonary Antihypertensives 2) By Drug Type: Antihistamines, Expectorants, Bronchodilators, Decongestants, Antibiotics, Other Types 3) By Dosage Type: Oral Syrups, Tablets/Pills, Nasal Drops, Lozenges, Other Dosage Types 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores

COVID-19 drug-associated APIs refer to the active pharmaceutical components that are employed in the production of COVID-19 medications. Chemicals called "active pharmaceutical components" serve as the foundation for pharmaceutical drugs and medicines and are responsible for pharmacological activity in the human body. The main classes of drugs in COVID-19 drug-associated APIs are antimalarials, bronchodilators, antibiotics, antivirals, and others. Antimalarial drugs, or simply "antimalarials," are antiparasitic chemical agents that can be used to cure or prevent malaria. They are generally organically sourced. The different types of drugs include generic, branded, and involve various modes of business such as captive API and merchant API. The COVID-19 drug-associated APIs market research report is one of a series of new reports from The Business Research Company that provides COVID-19 drug-associated APIs market statistics, including global market size, regional shares, competitors with a COVID-19 drug-associated APIs market share, detailed COVID-19 drug-associated APIs market segments, market trends and opportunities, and any further data you may need to thrive in the COVID-19 drug-associated APIs industry. This COVID-19 drug-associated APIs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global covid19 drug associated apis market grew from $5.99 billion in 2022 to $6.37 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The covid19 drug associated apis market is expected to grow from $8.02 billion in 2027 at a CAGR of 5.9%. High demand for some antiretrovirals, antimalarials, sedatives, bronchodilators and other respiratory drugs drives the demand for the active pharmaceutical ingredients (APIs) used in the production of COVID-19 drugs. Active pharmaceutical ingredients (APIs) are the biologically active component used in manufacturing pharmaceutical drugs. Remdesivir and Favipiravir are two common antiviral medications used currently for the treatment of COVID-19 patients. Remdesivir is a medication approved for emergency use in the USA and Japan for the treatment of COVID-19 patients. Remdesivir received emergency use authorization (EUA) from the FDA on May 1, 2020, based on its preliminary data showing a faster time to recovery in hospitalised patients with several diseases. Favipiravir, which is used to treat influenza in Japan, has also shown a positive effect on COVID patients. As COVID-19 is a respiratory ailment, the demand for bronchodilators spiked significantly. Therefore, the increasing demand for antivirals, antimalarials, and bronchodilators is projected to boost the demand for the COVID-19-associated drug APIs market over the forecast period. The disruptions caused by the COVID-19 outbreak in the supply chain of medical products limited the growth of the COVID-19 drug-associated APIs market in the past few months. The source for APIs plays a crucial part in the strategic plan to combat the COVID-19 pandemic. The majority of APIs for generic drug manufacturing across the globe are sourced from India, with nearly 30% of generic APIs used in the USA. The restrictions imposed on the export of pharmaceutical products owing to COVID-19 supply chain disruptions restricted market growth. For instance, India imposed an export ban on 26 pharmaceutical products and medical devices in March 2020. The ban was imposed due to API and other bulk drug supply chain disruptions caused by restrictive measures such as lockdowns and factory closures in many countries around the world to ensure disease containment.Thus, shortages caused by disruptions in supply chains and restrictions imposed on the export of pharma products impacted the growth of the COVID-19 drug-associated APIs market over the last few months. Key players operating in the pharmaceutical industry that manufactures COVID-19 drug-associated APIs are focusing on strategies such as plant capacity or production capacity expansion to meet the increasing demand due to the rising number of coronavirus cases across the globe. For instance, in March 2020, Alembic Pharmaceuticals Ltd announced that the company is ramping up the production for the company’s production for azithromycin to 20 tonnes per month. Likewise, In April 2020, FUJIFILM Corporation announced the expansion of its manufacturing capacity and increase in the production of influenza antiviral Avigan Tablet (Favipiravir) by nearly 2.5 times by the end of July. Avigan is currently undergoing clinical trials testing its safety and efficacy for the treatment of COVID-19 patients. In February 2020, Dr. Reddy Labs announced the acquisition of the branded generics business of Wockhardt for an amount of $242 million (INR 1,850 crore). The acquisition is expected to scale up the former company’s presence in home markets including India, Nepal, Sri Lanka, Bhutan, and the Maldives. The Wockhardt business consists of a product portfolio of 62 brands in multiple therapy fields such as dermatology, neurology, respiratory, VMS, pain, gastroenterology, and vaccine. Wockhardt Ltd. was founded in 1999 and is a global biotechnology and pharmaceutical company based in Mumbai, India. Major players in the COVID-19 drug-associated APIs market are Dr. Reddy's Laboratories, Lianyungang Guike Pharmaceutical, Alembic Pharmaceutical, Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical (Haimen) Co. Ltd., and Yatai Pharma. North America is the largest region in the COVID-19 drug-associated APIs market in 2022. Middle East is expected to be the fastest growing region in the global COVID-19 drug associated apis market during the forecast period. The regions covered in the global COVID-19 drug-associated APIs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the COVID-19 drug-associated APIs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The COVID-19 drug associated APIs market consists of sales of acetaminophen (Tylenol) and ibuprofen (Motrin, Advil). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global COVID-19 drug associated apis market is segmented - 1) By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class 2) By Synthesis Type: Synthetic, Biotech 3) By Business Mode: Captive API, Merchant API

Feed premix refers to a mixture of one or more feed additives that are included in the diet of livestock animals and are not intended for direct consumption. Premix includes vitamins, trace minerals, medicaments, feed supplements, and diluents as its constituents. It's a value-added solution for feeds with long-term quality and safety. The main types of feed premix are amino acids, antioxidants, antibiotics, vitamins, minerals and others. The amino acids feed premix contains L-lysine, DL-methionine, and L-threonine which improves the synthetic efficiency of protein. The availability of those components permits a user to anticipate an increase in protein synthesis efficiency. The feed premix are available in two form namely dry and liquid and are used by livestock such as ruminants, swine, aquatic animals, poultry and pets. The feed premix market research report is one of a series of new reports from The Business Research Company that provides feed premix market statistics, including feed premix industry global market size, regional shares, competitors with a feed premix market share, detailed feed premix market segments, market trends and opportunities, and any further data you may need to thrive in the feed premix industry. This feed premix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global feed premix market size grew from $19.2 billion in 2022 to $20.63 billion in 2023 at a compound annual growth rate (CAGR) of 7.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The feed premix market size is expected to grow to $30.12 billion in 2027 at a CAGR of 9.9%. The increase in the demand and consumption of livestock-based products is expected to propel the growth of the feed premix market. Livestock-based products comprise eggs, dairy products, and meat products. Adding feed premix to the livestock's diet helps in providing sufficient vitamins and minerals and enhances nutrition and better production of livestock-based products such as milk. An increase in the adoption and consumption of dairy and meat products is increasing the sales of livestock-based products which is driving the demand for feed premix. For instance, according to the U.S. Department of Agriculture (USDA) data, dairy consumption in America, in 2020, was around 655 pounds of dairy in milk, yogurt, cheese, butter, ice cream, and other wholesome and nutritious dairy foods, which is an increase of 3 pounds per person from 2019. Therefore, an increase in the demand and consumption of livestock-based products will drive the growth of the feed premix market. The development of a new feed ingredient is a key trend gaining popularity in the feed premix market. Advancement in the properties of feed ingredients will lead to improved properties of feed premixes which will benefit the consuming livestock. These new feed ingredients provide additional benefits such as improving health and maximizing production. For instance, in December 2021, BASF, a Germany-based chemical company, developed Natupulse TS, a revolutionary feed enzyme to release priceless nutrients. A non-starch polysaccharide (NSP) enzyme is Natupulse® TS. It hydrolyzes ß-mannans into smaller components, such as manno-oligosaccharides, as an endo-1,4-ß-D-mannanase (MOS). When ß-mannanase is added to the feed, the digesta viscosity is reduced, the feed's digestibility is increased, and a more sustainable output is ensured. In October 2020, Royal DSM, a Dutch company involved in the fields of health, nutrition, and materials acquired Erber Group for USD 1.04 billion. This acquisition is expected to strengthen DSM's experience and reputation as a leading provider of nutrition solutions for animals and will also help in reducing emissions, feed utilization efficiency, and enhancing water and land utilization. Erber Group is an Austrian company involved in the animal nutrition and health business. Major players in the feed premix market are Advanced Animal Nutrition Pty Ltd., Archer Daniels Midland Company, BASF SE, BEC Feed Solutions Pvt Ltd., Cargill Incorporated, Danish Agro Group, Dansk Landbrugs Grovvareselskab, De Heus Voeders BV, Phibro Animal Health Corporation, ForFramers BV, Godrej Agrovet Limited, Invivo NSA, Koninklijke Coöperatie Agrifirm UA, Koninklijke DSM, Land O'Lakes Inc., Nutreco NV, AB Agri Ltd., Agrofeed Ltd., Avitech Nutrition Pvt Ltd., DSM Austria GmbH (Biomin), Beijing Da Bei Nong Science and Technology Group Co Ltd (DBN Group), Burkmann Industries Inc., Purina Animal Nutrition LLC and Hi-Nutrients International Limited. Asia-Pacific was the largest region in the feed premix market in 2022. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the feed premix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the feed premix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The feed premix market consists of sales nucleotides, trace elements, and other functional ingredients. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global feed premix market is segmented - 1) By Type: Amino Acids, Antioxidants, Antibiotics, Vitamins, Minerals, Other Types 2) By Form: Dry, Liquid 3) By Livestock: Ruminants, Swine, Aquatic Animals, Poultry, Pets

Cattle feed additives refer to the products that are used to increase cattle nutrition and are added to cattle feed to provide complete nutrition to farm cattle. These are ground, pelleted, crumbled, or mixed feed used for feeding cattle. These feeds are balanced for various nutrients as per cattle needs. Feed additives are compounds fed to cattle for reasons other than supplying nutrients, such as promoting good cattle health and improving their growth. The main types of ingredients in cattle feed and feed additives are corn, soybean meal, wheat, oil seeds, grains, and others. Corn is used as livestock feed, biofuel, and raw material in the farm industry. Corn is a tall American cereal grass plant widely grown for its large ears of starchy grain, which come in wide varieties. The different products include antibiotics, vitamins, antioxidants, amino acids, feed enzymes, and acidifiers and involve various applications such as beef cattle, dairy cattle, calves and others. The cattle feed and feed additives market research report is one of a series of new reports from The Business Research Company that provides cattle feed and feed additives market statistics, including global market size, regional shares, competitors with a cattle feed and feed additives market share, detailed cattle feed and feed additives market segments, market trends and opportunities, and any further data you may need to thrive in the cattle feed and feed additives industry. This cattle feed and feed additives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry. The global cattle feed and feed additives market size grew from $57.12 billion in 2022 to $59.74 billion in 2023 at a compound annual growth rate (CAGR) of 4.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cattle feed and feed additives market size is expected to grow to $68.51 billion in 2027 at a CAGR of 3.5%. The growing livestock and animal husbandry industry is expected to propel the growth of the cattle feed and feed additives market going forward. Livestock refers to cattle, sheep, horses, goats, and other domestic animals ordinarily rose on a farm. Cattle feed and feed additives are used on farms for raising livestock and animals, which helps to add nutrients to their food and aids their faster growth. For instance, according to data by Eurostat, a Luxemburg-based Directorate-General of the European Commission, in the 2021 political and economic union of 27 European nations, the livestock population of Europe is valued at 297 million, which is 146 million pigs, 76 million bovine animals, and 75 million sheep and goats. Therefore, the growing livestock and animal husbandry are driving the growth of the cattle feed and feed additives market. Technological advancements are a key trend gaining popularity in the cattle feed and feed additive market. Major companies operating in the cattle feed and feed additives sectors are focused on introducing new technologies to reinforce their position. For instance, in June 2021, Charoen Pokphand Foods PCL, a Thailand-based agro-industrial company, developed a unique feed formula that contains microorganisms and improves the digestive systems of farm animals through animal food that fits different ages and types of animals. This probiotic technology keeps animals healthy and strong without the use of growth hormones or antibiotics. The product also protects animals from diseases and improves immunity. In October 2020, Royal DSM NV, a Netherlands-based company that operates in the areas of nutrition, health, and sustainable living, acquired Erber Group for a deal amount of $ 982 million. This acquisition strengthens DSM’s expertise and market position in animal health and nutrition solutions. Erber Group is an Austria-based company that offers specialty animal nutrition products, such as feed additives and health solutions. Major players in the cattle feed & feed additives market are Adisseo France S.A.S, Archer Daniels Midland company, BASF SE, Biomin, Cargill Incorporated, Charoen Pokphand Foods PCL, Chr. Hansen Holding A/S, Country Bird Holdings Limited, Evonik Industries AG, Hansen Holdings, Kent Corporation, Land O'Lakes Inc., Nutr??? N.V., ?llt??h, Koninklijke DSM N.V., Elanco Animal Health Incorporated, Kemin Industries, and New Hope Group. Asia-Pacific was the largest region in the cattle feed and feed additives market in 2022. The regions covered in the cattle feed & feed additives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cattle feed & feed additives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cattle feed and feed additive market consists of sales of antibiotics, acidifiers, vitamins, and enzymes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cattle feed and feed additives market is segmented - 1) By Ingredient: Corn, Soyabean Meal, Wheat, Oil Seeds And Grains, Other Ingredients 2) By Product: Antibiotics, Vitamins, Antioxidants, Amino Acids, Feed Enzymes, Acidifiers, Other Products 3) By Application : Beef Cattle, Dairy Cattle, Calves, Other Applications

Peptide antibiotics refer to antibiotics made up of peptides the physical rupture of cell membranes underpins the antibacterial activity. The peptide antibiotics are used to permeate bacterial membranes, collect within bacteria, and then interfere with bacterial functioning. The main types of peptide antibiotics are ribosomal synthesized peptide antibiotics and non-ribosomal synthesized peptide antibiotics. The ribosomal synthesized peptide antibiotics destroy or modify the drug, change the drug target, decrease or raise drug uptake, and substitute a different metabolic step as the medication's target. Ribosomal synthesized peptide antibiotics refer to antimicrobial peptides generated by ribosomes and produced by practically all species, from bacteria to plants and animals. The various drugs under peptide antibiotics are daptomycin, dalbavancin, telavancin, and other drugs used to treat several diseases such as skin infection, HABP/VABP, blood stream infection, and other diseases. The peptide antibiotics are used and distributed through hospitals, homecare, specialty clinics, and other distribution channels. The peptide antibiotics market research report is one of a series of new reports from The Business Research Company that provides peptide antibiotics market statistics, including peptide antibiotics industry global market size, regional shares, competitors with a peptide antibiotics market share, detailed peptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide antibiotics industry. This peptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global peptide antibiotics market size grew from $4.23 billion in 2022 to $4.58 billion in 2023 at a compound annual growth rate (CAGR) of 8.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The peptide antibiotics market size is expected to grow to $6.22 billion in 2027 at a CAGR of 7.9%. The increase in the prevalence of various infectious diseases is expected to propel the growth of the peptide antibiotics market. Infectious diseases are illnesses caused by harmful micro-organisms such as bacteria, fungi, parasites, and others. The major reasons for the rise in infectious diseases are rapid urbanization, climate change, increasing risk of disease emergence, and others, which have increased the demand for peptide antibiotics. Peptide antibiotics physically rupture the cell membranes and underpins the antibacterial activity. For instance, in July 2022, according to the Australian Institute of Health and Welfare, an organization that provides data and statistics about Australia's welfare and health, the cases of notifiable infectious diseases in Australia grew from 2.89 million cases in 2020 to 7.02 million cases in 2021. It shows a significant growth in the total number of cases of infectious diseases. Therefore, the increase in the incidence of infectious is driving the growth of the peptide antibiotics market. The strategic partnership is a key trend gaining popularity in the peptide antibiotics market. Major companies operating in the peptide antibiotics market are entering into partnerships to expand their market and leverage each others resources. For intsance, in January 2022, Berkeley Lights, a US-based digital cell biology company, partnered with Aanika Biosciences. In this partnership, Aanika will leverage Berkeley Lights' high-throughput, functional screening service to swiftly find and refine functional antimicrobial peptides (AMPs) capable of eliminating dangerous bacteria, particularly those that cause foodborne disease outbreaks. Furthermore, the Beacon Optofluidic Platform will be used to identify peptides that are harmful to bacteria in order to develop a novel antibacterial tag, which will then be used in their bacterial spore-based barcoding technology to secure the food supply chain. Aanika Biosciences is a US-based biotechnology company. An increase in incidence of chronic diseases is expected to drive the peptide antibiotics market. Chronic diseases are illnesses that last a year or longer, demand ongoing medical attention, and limit daily activities. Chronic diseases are on the rise as a result of increased tobacco use, poor nutrition, physical inactivity, excessive alcohol consumption, and other factors. Peptide antibiotics are used to treat chronic diseases by administering the drug in the target area. For instance, in July 2021, the National Council on Aging, Inc., a US-based charitable organization, reported that over 85% of elderly people have at least one chronic illness, and health care spending rose to $3.8 trillion annually in the US. Also, according to a research report published by American Action Forum in September 2020, chronic disease prevalence and costs are rising in the United States. They are expected to keep rising as the disease prevalence among children and young adults rises. Chronic disease is a serious healthcare problem since the rising cost of chronic disease in the United States totals $3.7 trillion annually, around 19.6% of the country's gross domestic product. Therefore, the increasing prevalence of chronic conditions is fueling the growth of the peptide antibiotics market. Major players in the peptide antibiotics market are Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Theravance Biopharma, Pacgen Life Science Corporation, Kasten, Savara Pharmaceuticals, Merck KGaA, Madam Therapeutics, Allergan PLC., Dr. Reddy’s Laboratories Ltd., Sanofi, Fresenius Kabi AG, Novo Holdings A/S and Teva Pharmaceutical Industries Ltd. North America was the largest region in the peptide antibiotics market in 2022. The regions covered in the peptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the peptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The peptide antibiotics market consists of sales of oral, intravenous, intramuscular and topical peptide antibiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global peptide antibiotics market is segmented - 1) By Type: Ribosomal Synthesized Peptide Antibiotics, Non-rRibosomal Synthesized Peptide Antibiotics 2) By Drugs: Daptomycin, Dalbavancin, Telavancin, Other Drugs 3) By Disease Outlook: Skin Infection, HABP/VABP, Blood Stream Infection, Other Diseases 4) By Distribution Channel: Hospitals, Homecare, Specialty Clinics, Other Distribution Channels

Atopic dermatitis is a dermatological condition that causes dryness and itching of the skin. It is a chronic condition that progresses over time and is not spread by contact. The main drug classes to treat atopic dermatitis include corticosteroids, emollients/moisturizers, IL-4 and PDE4 inhibitors, calcineurin inhibitors, antibiotics, and others. Corticosteroids refer to anti-inflammatory drugs that resemble cortisol and are used to treat a variety of diseases such as rheumatological diseases, rheumatoid arthritis, lupus, and atopic dermatitis. These are delivered through various modes of administration, including topical, injectable, and oral, and sold through several distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies. The atopic dermatitis market research report is one of a series of new reports from The Business Research Company that provides atopic dermatitis market statistics, including atopic dermatitis industry global market size, regional shares, competitors with an atopic dermatitis market share, detailed atopic dermatitis market segments, market trends and opportunities, and any further data you may need to thrive in the atopic dermatitis industry. This atopic dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global atopic dermatitis market size is expected to grow from $6.48 billion in 2022 to $7.51 billion in 2023 at a compound annual growth rate (CAGR) of 15.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The atopic dermatitis market is expected to grow to $13.06 billion in 2027 at a CAGR of 14.9%. The high prevalence of atopic dermatitis is expected to propel the growth of the atopic dermatitis market forward. Atopic dermatitis, also called eczema, is a skin condition that causes dryness and itchiness of the skin. The increasing prevalence of atopic dermatitis increases the need for diagnosis and treatment of the disease. For instance, according to the National Eczema Association, a US-based organization working to spread awareness related to eczema, in 2021, 31.6 million people in the US had some form of eczema, which was about 10% of the total population. Approximately 9.6 million children under the age of 18 had atopic dermatitis, and 80% of the individuals were affected by dermatitis before the age of 6 years. Therefore, the increasing prevalence of atopic dermatitis is driving the growth of the atopic dermatitis market. Product innovations are a key trend gaining popularity in the atopic dermatitis market. Major companies in the market are introducing innovative products to strengthen their market position. For instance, in May 2020, Sanofi, a France-based pharmaceutical company, received FDA approval for its novel dupilumab drug Dupixent for the treatment of moderate-to-severe atopic dermatitis. It is the first and only biologic drug to receive approval for treating atopic dermatitis in children between the ages of 6 and 11. Children treated with it achieved clearer skin in just 16 weeks in the phase 3 trial, which was better than topical corticosteroids alone. In September 2022, Arcutis Biotherapeutics, a US-based commercial-stage biopharmaceuticals company, acquired Ducentis BioTherapeutics for an undisclosed amount. The acquisition would help Arcutis achieve its vision of leading the medical dermatology market and would help it develop medications for the unmet dermatological needs of its patients. Ducentis BioTherapeutics is a US-based preclinical-stage biotechnology company developing lead indications for atopic dermatitis. Major players in the atopic dermatitis market are Sanofi S.A., Meda AB, Regeneron Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Arcutis Biotherapeutics Inc., Asana Biosciences LLC, Dermavant Sciences Inc., Eli Lilly and Company, Galderma S.A., Incyte Corporation, Bayer AG,  Bausch Health Companies Inc.,  Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, and F. Hoffmann-La Roche AG. North America was the largest region in the atopic dermatitis market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the atopic dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The atopic dermatitis market consists of sales of biologics, CNI immunosuppressant drugs, and skin barrier emollients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global atopic dermatitis market is segmented - 1) By Drug Class: Corticosteroids, Emollients/Moisturizers, IL-4 and PDE4 Inhibitors, Calcineurin Inhibitors, Antibiotics, Other Drug Classes 2) By Mode of Administration: Topical, Injectable, Oral 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The anti-infective drugs market consists of sales of branded and generic anti-infective drugs and related services by entities (organizations, sole traders and partnerships) that manufacture branded or generic anti-infective drugs to treat microbial infections. The anti-infective drugs industry includes establishments that manufacture antibiotics to treat bacterial infections, anti-viral drugs to treat viral infections, anti-fungal drugs to treat fungal infections, anti-helminthic drugs to kill internal parasites, and antiprotozoal agents to treat protozoan infections. The main types of anti-infective drugs are antibiotics, antivirals, antifungals and others (anthelminthic, antiprotozoal). Antibiotics are drugs that either kill or slow the growth of bacteria. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global anti-infective drugs market size is expected to decline from $220.0 billion in 2021 to $246.80 billion in 2022 at a compound annual growth rate (CAGR) of 12.2%. The change in the anti-infective drugs market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The anti-infective drugs market is expected to reach $614.29 billion in 2026 at a CAGR of 25.6%. The anti-infective drugs market is expected to benefit from the latest developments in drug discovery procedures such as stem cells and organ-on-chip (OOC) technologies. OOCs are micro-engineered biometric systems that simulate the activities, mechanics and physiological responses of organ systems. Drug trial processes such as target identification, validation, and screening are being executed through OOC and stem cell technologies. These technologies are considerably reducing the drug discovery costs and generating reliable predictions on drug efficiency and human safety. Another area of development is physiology-simulation modelling, in which the integrated physiology of the human organism, in both health and disease, is simulated through a computer program. Eli Lilly and Pfizer have adopted Amazon’s Elastic Compute Cloud (EC2) platform to conduct simulation models in early stages of the drug discovery process that are operational within hours, whereas traditional models take weeks to conduct simulations. The wide adoption of these technologies is expected to drive the anti-infective drugs market in the forecast period. The anti-infective drugs market is expected to be restrained by the increasing number of antimicrobial resistance cases due to growing ineffectiveness of conventional anti-infective drugs such as penicillin. Antimicrobial resistance is the final stage of the adaptation process of microorganisms such as bacteria to the environment developing the ability to resist the effects of anti-infective drugs. This is mainly caused by the overuse and misuse of anti-infective drugs such as antibiotics. The excessive use and misuse of anti-infective drugs increases the rate of the bacteria’s resistance, with an estimated 70% of bacteria ever discovered already being resistant to at least one anti-infective drug which was commonly used to treat them in the past. It is expected that deaths caused by antimicrobial resistance will rise to 10 million deaths by 2050. Increasing incidences of bacteria’s resistance to anti-infective drugs are expected to limit the use of anti-infective drugs, affecting the market’s growth. Anti-infective drug manufacturers are investing in programs to develop drugs to treat drug resistant infections. Antimicrobial resistance is a serious concern to global public health as it resulted in long duration of illness, the requirement of additional tests and use of more expensive drugs. Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, parasites and fungi change and adapted to drugs when they are exposed to antimicrobial drugs such as antibiotics, antivirals, antifungals, anthelmintics and others. According to World Health Organization (WHO), globally 4, 80,000 people are being affected by multi-drug resistant TB each year and drug resistance is starting to complicate the treatment of malaria and HIV as well. Companies are investing in developing the new drug candidates to treat drug-resistant infections. For instance, in 2019, the antibacterial agents imipenem, cilastatin and relebactam combination, pretomanid, lefamulin, and cefiderocol was approved by the US FDA in the field of resistant bacteria treatment for specific indications. Major companies in the anti-infective drugs market include Gilead Sciences, GlaxosmithKline, Merck & Co, Johnson & Johnson, Pfizer Inc., AbbVie, Bayer AG, Mylan N.V., Shionogi and F. Hoffmann-La Roche Ltd. North America was the largest region in the anti-infective drugs in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anti-infective drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global anti-infective drugs market is segmented - 1) By Type: Antibiotics, Antivirals, Antifungals, Others (Anthelminthic, Antiprotozoal) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs